Read the story behind the quarter.
Income statement, balance sheet, and cash flow—connected to the customer situation, marketing choices, operating indicators, and real competitive alternatives.
Five reports to start with
Medtronic FY2026 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Medtronic reported $36.4B in revenue and $6.5B in operating profit for FY2026. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2026 · STESTERIS FY2026 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
STERIS reported $5.9B in revenue and $1.1B in operating profit for FY2026. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2026 · CRVLCorVel FY2026 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
CorVel reported $959M in revenue and $110M in operating profit for FY2026. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2026 · HAEHaemonetics FY2026 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Haemonetics reported $1.3B in revenue and $157M in operating profit for FY2026. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2026 · DOCSDoximity FY2026 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Doximity reported $645M in revenue and $215M in operating profit for FY2026. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →121 earnings analyses
Primary sources · US GAAP · USD millions
Repligen FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Repligen reported $738M in revenue and $55M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · XRAYDentsply Sirona FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Dentsply Sirona reported $3.7B in revenue and -$422M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · BMRNBioMarin Pharmaceutical FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
BioMarin Pharmaceutical reported $3.2B in revenue and $409M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · LNTHLantheus Holdings FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Lantheus Holdings reported $1.5B in revenue and $311M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · IARTIntegra LifeSciences FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Integra LifeSciences reported $1.6B in revenue and -$493M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · PRCTPROCEPT BioRobotics FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
PROCEPT BioRobotics reported $308M in revenue and -$104M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · OMCLOmnicell FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Omnicell reported $1.2B in revenue and $5M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · EHCEncompass Health FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Encompass Health reported $5.9B in revenue and $759M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · NVCRNovocure FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Novocure reported $655M in revenue and -$154M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · NHCNational HealthCare Corporation FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
National HealthCare Corporation reported $1.5B in revenue and $128M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · TDOCTeladoc Health FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Teladoc Health reported $2.5B in revenue and -$263M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · VCYTVeracyte FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Veracyte reported $517M in revenue and $58M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · IONSIonis Pharmaceuticals FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Ionis Pharmaceuticals reported $944M in revenue and -$382M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · VTRSViatris FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Viatris reported $14.3B in revenue and -$2.7B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · ACADAcadia Pharmaceuticals FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Acadia Pharmaceuticals reported $1.1B in revenue and $105M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · EWEdwards Lifesciences FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Edwards Lifesciences reported $6.1B in revenue and $1.3B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · UTHRUnited Therapeutics FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
United Therapeutics reported $3.2B in revenue and $1.5B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · PENPenumbra FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Penumbra reported $1.4B in revenue and $189M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · LFSTLifeStance Health Group FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
LifeStance Health Group reported $1.4B in revenue and $24M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · ALKSAlkermes FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Alkermes reported $1.5B in revenue and $254M in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · MRKMerck & Co. FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Merck & Co. reported $65B in revenue and $18.3B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · GILDGilead Sciences FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Gilead Sciences reported $29.4B in revenue and $10B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · DHRDanaher FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Danaher reported $24.6B in revenue and $4.7B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →FY2025 · LHLabcorp FY2025 Earnings: How turning clinical evidence, access, adherence, and professional trust shaped growth and margin
Labcorp reported $14B in revenue and $1.4B in operating profit for FY2025. We connect the customer situation and business mechanism to the income statement, balance sheet, and cash flow.
Read earnings analysis →
